



UNITED STATES  
NUCLEAR REGULATORY COMMISSION

REGION III  
2056 WESTINGS AVENUE, SUITE 400  
NAPERVILLE, IL 60563-2657

December 18, 2024

Samer Salka, M.D.  
Radiation Safety Officer  
Premier Cardiovascular Specialists  
20200 W. Outer Dr.  
Dearborn, MI 48124

Dear Dr. Salka:

This letter is regarding your request dated August 5, 2024, for agency consent to the transfer of control of U.S. Nuclear Regulatory Commission (NRC) Materials License No. 21-32740-01.

The U.S. NRC's guidance document applicable to your request, which I refer to as "the guidance" elsewhere in this document is NUREG-1556, Volume 15, Rev. 1, "Consolidated Guidance About Materials Licenses: Guidance About Changes of Control and About Bankruptcy Involving Byproduct, Source, or Special Nuclear Materials Licenses," dated June 2016. This guidance is available on the U.S. NRC's website at:  
<https://www.nrc.gov/docs/ML1618/ML16181A003.pdf>

Upon review of the request, I identified the following areas requiring additional or clarifying information:

1. Appendix E, "Information Needed for Transfer of Control Application," of the guidance identifies the information needed to evaluate a proposed transfer of control application. Your application provided much of the information from this appendix.

The following items were either not addressed or lacked adequate detail.

- Describe any planned changes in the organization, including but not limited to, transfer of stocks or assets and mergers, change in members on Board of Directors, etc. Provide the new licensee's name, mailing address, and contact information, including phone numbers. Clearly identify when the amendment request is due to a name change only.
- Confirm that both transferor and transferee agree to transferring control of the licensed material and activity, and the conditions of transfer, and that the transferee has been made aware of any open inspection items and its responsibility for possible resulting enforcement actions.

Additional items in this letter provide additional detail about the information needed to support the evaluation of the proposed change of control. Further information regarding completion of the license application may be found in Section 5, "Change of Control," of the guidance.

2. Section 5.1, "Description of Transaction," of the guidance specifies that a complete and clear description of the transaction must be provided.

The description should include all of the following as applicable:

- identification of any changes in the organization, including but not limited to, transfer of stocks or assets and mergers, change in members of Board of Directors, etc.;
- the new legal name of the licensed organization;
- new licensee contact and telephone number(s) to facilitate communications; and
- pre- and post-transaction organizational chart showing the corporate structure of the license holder and its parent companies, if any.

Upon review of the description of the proposed transaction, it appears that *PREMIER CARDIOVASCULAR SPECIALISTS* (transferor) will be purchased by *HENRY FORD HEALTH* (transferee) and will operate under the legal name identified as *HENRY FORD HEALTH*.

A check with the Michigan Licensing and Regulatory Affairs' Corporations Division revealed that the complete and correct name of the transferee is *HENRY FORD HEALTH SYSTEM, d/b/a Henry Ford Health*. Please confirm that the complete and correct name of the transferee is *HENRY FORD HEALTH SYSTEM, d/b/a Henry Ford Health*.

3. Section 5.6, "Transferee's Commitment to Abide by the Transferor's Commitments," must either commit to abide by all constraints, license conditions, requirements, representations and commitments identified in and attributed to the existing license or provide a description of its own program to comply with the license and all applicable regulations.

Please confirm that both transferor and transferee agree to transferring control of the licensed material and activity, and the conditions of transfer, and that the transferee has been made aware of any open inspection items and its responsibility for possible resulting enforcement actions. Further, please confirm that the transferee will abide by all constraints, conditions, requirements, representations, and commitments of the transferor.

In accordance with [10 CFR §2.390](#) of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be made available electronically for public inspection in the NRC Public Document Room or from the NRC's Agencywide Documents Access and Management System (ADAMS), accessible from the NRC Web site at <https://www.nrc.gov/reading-rm/adams.html>.

To continue review of your request, please submit your response to this letter within 15 calendar days from the date of this letter. In your response, please refer to the license, docket, and control number specified below. I will assume that you do not wish to further pursue this licensing action if I do not receive a reply within the specified timeframe noted above.

If you have questions, require additional time to respond, or require clarification on any of the information stated above, I encourage you to contact me at (630) 829-9737 or via e-mail at [Jason.Kelly@nrc.gov](mailto:Jason.Kelly@nrc.gov).

Sincerely,

Jason M. Kelly, MPH, CPH  
Health Physicist  
Materials Licensing Branch

Control No.: 642205  
Docket No.: 030-38009  
License No.: 21-32740-01